Aug 24 (Reuters) - Biodel Inc (BIOD.O) said the review of its diabetes drug may be withheld due to a regulatory warning letter issued to a manufacturing facility that produced vials of Biodel's experimental diabetes drug, sending its shares down 11 percent.
